linjc16/ctgov huggingface dataset:
High Flow Nasal Canula Oxygen Helps Preoxygenate ARDS Patients

Study Overview
=================
Brief Summary
-----------------
Tracheal intubation in the ICU is associated with significant complications and morbidity. Desaturation is among the most frequent and hazardous complication, occurring in almost one out of four intubations, that may in some instances lead to cardiac arrest; despite appropriate preoxygenation. Non-invasive ventilation may help improve preoxygenation but does not allow for apneic oxygenation and may not be performed in patients with neurological impairment. High flow nasal canula oxygen is increasingly used in the ICU in patients with acute hypoxemic respiratory failure and may be used to improve preoxygenation. It is currently used in our ICU for that purpose. Because high flow nasal canula oxygen is our first line oxyten therapy for patients with acute respirtory distress syndrome, we sought to determine its use as a means to ensure preoxygenation in those ARDS patients that require intubation.

Detailed Description
-----------------
High flow nasal canula oxygen is increasingly used to provide heated and humidified oxygen in patients with acute respiratory failure. One of the major advantages of high flow nasal canula oxygen is the possibility to maintain oxygenation during laryngoscopy and thereby providing high flow apneic oxygenation. In addition, and contrary no non-invasive ventilation, preoxygenation may be used in patients with neurological impairment. Finally, the interest of this device is that it is the same that is maintained throughout the whole management of the patient, from ICU admission to intubation.

Official Title
-----------------
Observational Study of High Flow Nasal Canula Oxygen to Preoxygenate ARDS Patients That Require Intubation

Conditions
-----------------
Acute Respiratory Distress Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ARDS according to the Berlin criteria use of high flow nasal canula oxygen Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxygen saturation | oxygen saturation measured by pulse oxymetry during intubation and compared to levels before intubation | 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complications | arrhythmia, hypotension, profound desaturation, cardiac arrest | 60 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Respiratory Distress Syndrome, Adult, intubation, intratracheal, Oxygen Inhalation Therapy, Positive-Pressure Respiration, laryngoscopy
The Pretreatment of a Left-sided Double-lumen Tube to Prevent Its Misplacement to the Right Mainstem Bronchus

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether flexion of bronchial tip of a left-sided double lumen endobronchial tube prevents tube misplacement to the right mainstem bronchus.

Conditions
-----------------
Double Lumen Tube Intubation

Intervention / Treatment
-----------------
* Device: Neutral shape of bronchial tip
* Device: Bent shape of bronchial tip


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing thoracic surgery that require the placement of left-sided double-lumen tubes Exclusion Criteria: Abnormal anatomy of tracheobronchial tree Intraluminal lesion in the left or right mainstem bronchus Anticipated difficult intubation

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Neutral shape of bronchial tip<br> | Device: Neutral shape of bronchial tip<br>* Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.<br>|
| Experimental: Bent shape of bronchial tip<br> | Device: Bent shape of bronchial tip<br>* Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with intubation to right mainstem bronchus |  | An expected average of 5minutes after intubation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with airway injury |  | An expected average of 5 minutes after bilateral lung ventilation |
Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to prove the bioequivalence of Mycophenolate Mofetil 250 mg Capsules under fed conditions.

Official Title
-----------------
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions

Conditions
-----------------
Prophylaxis of Organ Rejection

Intervention / Treatment
-----------------
* Drug: mycophenolate mofetil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to mycophenolate mofetil or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: mycophenolate mofetil|mycophenolate mofetil 250 mg capsule|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bioequivalence determined by statistical comparison Cmax |  | baseline, 2-period, 14 day washout |
Assessment of EyeArt Performance With Retinal Imaging Devices

Study Overview
=================
Brief Summary
-----------------
The study evaluates the performance of the EyeArt system for detecting diabetic retinopathy from images captured using multiple retinal imaging devices and operators.

Official Title
-----------------
Assessment of EyeArt Performance With Retinal Imaging Devices

Conditions
-----------------
Diabetic Retinopathy

Intervention / Treatment
-----------------
* Procedure: Color fundus photography
* Drug: Mydriatic Agent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A diagnosis of diabetes mellitus; Understanding of study and provision of written informed consent; and 22 years of age or older. Exclusion Criteria: Persistent visual impairment in one or both eyes; History of macular edema, severe non-proliferative retinopathy, proliferative retinopathy, or retinal vascular (vein or artery) occlusion; History of ocular injections, laser treatment of the retina, or intraocular surgery other than cataract surgery without complications; Subject is contraindicated for fundus photography (for example, has light sensitivity); Subject has contraindications for mydriatic medications or is unwilling or unable to dilate; Subject is currently enrolled in an interventional study of an investigational device or drug; or Subject has a condition or is in a situation which in the opinion of the Investigator, might confound study results, may interfere significantly with the subject's participation in the study, or may result in ungradable dilated fundus photographs.

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Color fundus photography|Subjects will undergo fundus photography before and/or after administration of mydriatic agent|
|Drug: Mydriatic Agent|Subjects may be administered mydriatic medication to dilate their pupils.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Agreement between multiple EyeArt operations |  | 1 visit (1 day) |
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass

Study Overview
=================
Brief Summary
-----------------
The study is being undertaken to understand how the Roux-en-Y Gastric Bypass procedure can affect insulin secretion after meals. The hypothesis of this study is the Disposition Index is decreased in subjects who had previously undergone Roux-en-Y Gastric Bypass by glucagon-like peptide-1 (GLP-1) receptor blockade.

Official Title
-----------------
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Exendin 9, 39
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Roux-en-Y Gastric Bypass (RYGB)Subjects: Subjects who have undergone RYGB Inclusion Criteria Healthy Subjects: Must match RYGB subjects in age, weight, and gender Subjects will be without active systemic illness Exclusion Criteria all Subjects: Subjects <20 years old and >70 years old For Female Subjects: positive pregnancy text at the time of enrollment or study Subjects with functional or organic bowel symptoms.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exendin 9, 39<br>Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period. | Drug: Exendin 9, 39<br>* Exendin 9,39 is a competitive antagonist of endogenous GLP-1.<br>|
| Placebo Comparator: Placebo<br>A saline infusion will be administered in either first intervention period or second intervention period. | Drug: Placebo<br>* A saline infusion will be given to match the study drug infusion.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Total Disposition Index from Study 1 (Exendin 9,39) to Study 2 (saline) | The total disposition index equals the product of insulin secretion and insulin sensitivity. | Day 1, Day 2 (approximately 2 weeks after day 1) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gastric Bypass, bariatric surgery, carbohydrate metabolism
Transcranial Alternating Current Stimulation (tACS) for Auditory Hallucinations

Study Overview
=================
Brief Summary
-----------------
Transcranial alternating current stimulation (tACS) can modulate and restore neural oscillations that are reduced in patients with psychiatric illnesses such as schizophrenia. Here, we performed a open-lable study of clinical trial in 30 schizophrenia patients with auditory hallucinations to show that tACS is effective for auditory hallucinations.

Detailed Description
-----------------
Each week, the patient rested quietly with her eyes open while receiving alpha-frequency tACS for 40 minutes. Stimulation was delivered at 10 Hz with 1 mA zero-to-peak amplitude in-phase to the location 1 and the location 2 acquired by the MEG technique with 5*5 cm electrodes. A 5* 7 cm return electrode was centered on Cz. In total, 20 weeks.

Official Title
-----------------
Intervention Treatment of Auditory Hallucination by Transcranial Alternating Current Stimulation

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Device: tACS for auditory hallucinations via single arm


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Schizophrenia with auditory hallucinations was diagnosed by DSM-IV, AHRS >12, Take sufficient antipsychotics for at least 1 month. Exclusion Criteria: current pregnancy, major medical illness affecting the central nervous system, significant neurologic disorders, intake of drugs including supplements like essential fatty acids that influence prostaglandins or niacin skin flush flash pathway metabolism, a history of suicide risk, or alcohol or drug abuse.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: schizophrenia patients with auditory hallucinations<br>For schizophrenia patients with auditory hallucinations, tACS for implementation intervention | Device: tACS for auditory hallucinations via single arm<br>* a 20 weeks, weekly 40 minutes, 1mA, 10Hz-tACS protocol<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of Auditory Hallucination Scale(the minimum is 0, maximum value is 47, and higher scores mean a worse outcome) | Reduction rate of AHRS scale | One month |
Effect of Hypocalcemia on the Outcome of Elderly Major Trauma Patients With Trauma-induced Coagulopathy

Study Overview
=================
Brief Summary
-----------------
Hypocalcaemia is an independent risk factor of TIC in elderly trauma patients. TIC combined with hypocalcemia had worse coagulation function and more serious acidosis.

Detailed Description
-----------------
This 5-year retrospective, observational, single-center study was conducted at the Second Affiliated Hospital of Zhejiang University Medical School (SAHZU, China). Elderly patients with trauma were registered when they were admitted into intensive care unit affiliated to department of Emergency medicine (EICU) since January 2015 and September 2020.The purpose of this study is to elucidate the effect of hypocalcemia on TIC in elderly trauma patients through a single-center retrospective study, so as to further optimize the diagnosis and treatment strategies for TIC in elderly trauma patients.

Official Title
-----------------
Effect of Hypocalcemia on the Outcome of Elderly Major Trauma Patients With Trauma-induced Coagulopathy

Conditions
-----------------
Coagulopathy, Trauma

Intervention / Treatment
-----------------
* Other: hypocalcemia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age≥65 years old history of trauma Exclusion Criteria: previous anticoagulants or antiplatelet medication; Coagulopathy caused by previous underlying diseases; Blood products transfused before admission; Cardiac arrest on admission; Malignant tumor; Data incomplete

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| trauma induced coagulopathy<br>patients with INR>1.2 | Other: hypocalcemia<br>* hypocalcemia or normocalcemia<br>|
| non-trauma induced coagulopathy<br>patients with INR≤1.2 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Internationalized Normalized Ratio (INR) | coagulation function :Internationalized Normalized Ratio (INR) | 24 hour | 
| Activated Partial Thromboplastin Time (APTT) | coagulation function : Activated Partial Thromboplastin Time (APTT) | 24 hour | 
| Prothrombin Time (PT) | coagulation function : Prothrombin Time (PT) | 24 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood products rate | the rate of Blood products use | through study completion, an average of 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
trauma
A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the Automatic Fluid Shunt (AFS) can reduce the number of paracentesis procedures in patients with refractory ascites.

Official Title
-----------------
A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal

Conditions
-----------------
Refractory Ascites

Intervention / Treatment
-----------------
* Device: AFS System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female or male patients ≥ 18 years of age Removal of at least 10 L of ascites in the preceding 2 months for symptom relief Failure to respond to a maximum of 160 mg/d of furosemide and 400 mg/d of spironolactone (or equivalent doses of loop-acting and distal-acting diuretics), or intolerance to high dose diuretics because of hyponatremia, hyperkalemia, or other side-effects Dietary sodium restriction <90 mcg/d. Serum creatinine levels of less than 1.8 mg/dL for at least 7 days before study entry. Total bilirubin levels of less than 3 mg/dL. Expected survival of greater than 6 months Written informed consent Exclusion Criteria: Presence of recurring systemic or local infection, such as peritonitis, urinary tract infection, or abdominal skin infection. Presence of peritoneal carcinomatosis Evidence of extensive ascites loculation Obstructive uropathy Coagulopathy that could not be corrected to a prothrombin time INR <1.8, Thrombocytopenia that could not be corrected to a platelet count greater than 60,000/mm3 Any other clinically significant disease that could be adversely affected by study participation judged by the Investigator Any condition requiring emergency treatment Pregnancy Inability to obtain informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Automatic Fluid Shunt<br> | Device: AFS System<br>* AFS System with patient specific flow rate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of paracentesis procedures required |  | 6 month |
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma

Study Overview
=================
Brief Summary
-----------------
This study is a single-arm, open label, phase I clinical trial to evaluate the safety and feasibility of CD19CAR-T in treatment of relapsed / refractory non-hodgkin lymphoma

Official Title
-----------------
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma

Conditions
-----------------
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma

Intervention / Treatment
-----------------
* Combination Product: CD19 CART


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis with Relapsed or refractory Non Hodgkin Lymphoma with CD19 positive Age 18 to 65 years old, both male and female; Is expected to survive more than 12 weeks; Physical condition is good: 0-1 score ECOG score; No obvious abnormal heart, liver, kidney, no large wounds that haven't healed on the body; Into groups to participate in voluntarily, good adherence, can cooperate test observation, childbearing age women must be 7 days before starting treatment expert pregnancy test and the results were negative, and signed a written informed consent form. Exclusion Criteria: Organ failure, such as heart: Class III and IV; liver: to Child grading of liver function grade C; kidney: kidney failure and uremia stage; lung: symptoms of severe respiratory failure; brain: disorder of consciousness; Existing serious acute infection, uncontrollable, or have fester sex and chronic infection, wound in delay no more; Pregnancy and lactation women; Patients who have participated in other clinical trials or other clinical trials in the past 30 days; The Investigator believe the patients should not participate in this experiment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: study group<br>After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10^4 cells/kg in 36-96 hours | Combination Product: CD19 CART<br>* CD19 CART<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recovery rate of patients being treated with CD19CAR-T | the recovery rate of patients consists of complete recovery rate and partial recovery rate of patients being treated with CD19 CAR-T | 6 months |